Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial

by Thuy P. Nguyen, Quyet Do, Lan T. Phan, Duc V. Dinh, Hiep Khong, Luong V. Hoang, Thuong V. Nguyen, Hung N. Pham, Men V. Chu, Toan T. Nguyen, Quang D. Pham, Tri M. Le, Tuyen N.T. Trang, Thanh T. Dinh, Thuong V. Vo, Thao T. Vu, Quynh B.P. Nguyen, Vuong T. Phan, Luong V. Nguyen, Giang T. Nguyen, Phong M. Tran, Thuan D. Nghiem, Tien V. Tran, Tien G. Nguyen, Tuynh Q. Tran, Linh T. Nguyen, Anh T. Do, Dung D. Nguyen, Son A. Ho, Viet T. Nguyen, Dung T. Pham, Hieu B. Tran, Son T. Vu, Su X. Hoang, Trung M. Do, Xuan T. Nguyen, Giang Q. Le, Ton Tran, Thang M. Cao, Huy M. Dao, Thao T.T. Nguyen, Uyen Y Doan, Vy T.T. Le, Linh P. Tran, Ngoc M. Nguyen, Ngoc T. Nguyen, Hang T.T. Pham, Quan H. Nguyen, Hieu T. Nguyen, Hang L.K. Nguyen, Vinh T. Tran, Mai T.N. Tran, Truc T.T. Nguyen, Phat T. Ha, Hieu T. Huynh, Khanh D. Nguyen, Ung T. Thuan, Chung C. Doan, Si M. Do
Published 2022-07-01